An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Treatment Study
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2017
Price : $35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 11 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 02 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Feb 2016 as per ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History